Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, United States.
Department of Neurology, Weill Cornell Medicine, New York, NY, United States.
Front Endocrinol (Lausanne). 2024 Mar 4;15:1350318. doi: 10.3389/fendo.2024.1350318. eCollection 2024.
Despite evidence from preclinical studies suggesting estrogen's neuroprotective effects, the use of menopausal hormone therapy (MHT) to support cognitive function remains controversial.
We used random-effect meta-analysis and multi-level meta-regression to derive pooled standardized mean difference (SMD) and 95% confidence intervals (C.I.) from 34 randomized controlled trials, including 14,914 treated and 12,679 placebo participants.
Associations between MHT and cognitive function in some domains and tests of interest varied by formulation and treatment timing. While MHT had no overall effects on cognitive domain scores, treatment for surgical menopause, mostly estrogen-only therapy, improved global cognition (SMD=1.575, 95% CI 0.228, 2.921; =0.043) compared to placebo. When initiated specifically in midlife or close to menopause onset, estrogen therapy was associated with improved verbal memory (SMD=0.394, 95% CI 0.014, 0.774; =0.046), while late-life initiation had no effects. Overall, estrogen-progestogen therapy for spontaneous menopause was associated with a decline in Mini Mental State Exam (MMSE) scores as compared to placebo, with most studies administering treatment in a late-life population (SMD=-1.853, 95% CI -2.974, -0.733; = 0.030). In analysis of timing of initiation, estrogen-progestogen therapy had no significant effects in midlife but was associated with improved verbal memory in late-life ( = 0.049). Duration of treatment >1 year was associated with worsening in visual memory as compared to shorter duration. Analysis of individual cognitive tests yielded more variable results of positive and negative effects associated with MHT.
These findings suggest time-dependent effects of MHT on certain aspects of cognition, with variations based on formulation and timing of initiation, underscoring the need for further research with larger samples and more homogeneous study designs.
尽管临床前研究有证据表明雌激素具有神经保护作用,但使用更年期激素疗法(MHT)来支持认知功能仍然存在争议。
我们使用随机效应荟萃分析和多层次荟萃回归,从 34 项随机对照试验中得出汇总标准化均数差(SMD)和 95%置信区间(CI),包括 14914 名治疗组和 12679 名安慰剂组参与者。
MHT 与某些感兴趣的认知领域和测试之间的关联因制剂和治疗时机而异。虽然 MHT 对认知域评分没有总体影响,但针对手术绝经的治疗,主要是雌激素单独治疗,与安慰剂相比改善了整体认知(SMD=1.575,95%CI 0.228,2.921; = 0.043)。当从中期或接近绝经开始时开始使用时,雌激素治疗与改善语言记忆相关(SMD=0.394,95%CI 0.014,0.774; = 0.046),而老年期开始使用则没有效果。总体而言,与安慰剂相比,自然绝经的雌激素孕激素治疗与简易精神状态检查(MMSE)评分下降相关,大多数研究将治疗用于老年人群(SMD=-1.853,95%CI-2.974,-0.733; = 0.030)。在开始时间的分析中,雌激素孕激素治疗在中年时没有显著效果,但与老年时的语言记忆改善相关( = 0.049)。治疗持续时间>1 年与较短时间相比,视觉记忆恶化。对个别认知测试的分析得出了与 MHT 相关的正、负效应的更多可变结果。
这些发现表明 MHT 对认知的某些方面具有时间依赖性影响,其变化取决于制剂和开始时间,这突显了需要进一步进行具有更大样本量和更同质研究设计的研究。